Search research articles
Contact Us
Filters
Showing results (321-330 of 385) with videos related to
Page
of 39
Sort By:
The Journal of Urology
|
May 29, 2003
Grade progression and regression in recurrent urothelial cancer
Ali Borhan, Jay E Reeder, Mary J O'Connell, et al.
Elife
|
September 11, 2018
Intrinsic cooperativity potentiates parallel
Trevor R Sorrells, Amanda N Johnson, Conor J Howard, et al.
Anti-Cancer Drugs
|
February 1, 2007
Phase 1 study of escalating-dose OncoGel (ReGel/paclitaxel) depot injection, a controlled-release formulation of paclitaxel, for local management of superficial solid tumor lesions
Svetislava J Vukelja, Stephen P Anthony, James C Arseneau, et al.
Echocardiography (Mount Kisco, N.Y.)
|
April 11, 2012
Comparison of squatting stress echocardiography and dobutamine stress echocardiography for the diagnosis of coronary artery disease
P Anthony N Chandraratna, Vadim A Kuznetsov, Dilbahar S Mohar, et al.
Ultrasound in Medicine & Biology
|
March 5, 2004
Three-dimensional registration of prostate images from histology and ultrasound
Lawrence S Taylor, Brian C Porter, Gyongyi Nadasdy, et al.
The EMBO Journal
|
October 3, 2002
Mot1p is essential for TBP recruitment to selected promoters during in vivo gene activation
Jean-Christophe Andrau, Chris J C Van Oevelen, Hetty A A M Van Teeffelen, et al.
Molecular Endocrinology (Baltimore, Md.)
|
November 4, 2006
Transgelin functions as a suppressor via inhibition of ARA54-enhanced androgen receptor transactivation and prostate cancer cell growth
Zhiming Yang, Yu-Jia Chang, Hiroshi Miyamoto, et al.
Frontiers in Pharmacology
|
October 5, 2023
Utility of pharmacogenetic testing to optimise antidepressant pharmacotherapy in youth: a narrative literature review
Bradley Roberts, Zahra Cooper, Stephanie Lu, et al.
Investigational New Drugs
|
April 12, 2012
Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg/m(2) every 21 days in patients with cancer
Glen J Weiss, Ross C Donehower, Tara Iyengar, et al.
Echocardiography (Mount Kisco, N.Y.)
|
April 13, 2012
Implications of acute left ventricular remodeling during squatting stress echocardiography
P Anthony N Chandraratna, Dilbahar S Mohar, Peter F Sidarous, et al.
Page
of 39
Search research articles
Search
Showing results (321-330 of 385) with videos related to
Sort By:
Page
of 39
The Journal of Urology
|
May 29, 2003
Grade progression and regression in recurrent urothelial cancer
Ali Borhan, Jay E Reeder, Mary J O'Connell, et al.
Elife
|
September 11, 2018
Intrinsic cooperativity potentiates parallel
Trevor R Sorrells, Amanda N Johnson, Conor J Howard, et al.
Anti-Cancer Drugs
|
February 1, 2007
Phase 1 study of escalating-dose OncoGel (ReGel/paclitaxel) depot injection, a controlled-release formulation of paclitaxel, for local management of superficial solid tumor lesions
Svetislava J Vukelja, Stephen P Anthony, James C Arseneau, et al.
Echocardiography (Mount Kisco, N.Y.)
|
April 11, 2012
Comparison of squatting stress echocardiography and dobutamine stress echocardiography for the diagnosis of coronary artery disease
P Anthony N Chandraratna, Vadim A Kuznetsov, Dilbahar S Mohar, et al.
Ultrasound in Medicine & Biology
|
March 5, 2004
Three-dimensional registration of prostate images from histology and ultrasound
Lawrence S Taylor, Brian C Porter, Gyongyi Nadasdy, et al.
The EMBO Journal
|
October 3, 2002
Mot1p is essential for TBP recruitment to selected promoters during in vivo gene activation
Jean-Christophe Andrau, Chris J C Van Oevelen, Hetty A A M Van Teeffelen, et al.
Molecular Endocrinology (Baltimore, Md.)
|
November 4, 2006
Transgelin functions as a suppressor via inhibition of ARA54-enhanced androgen receptor transactivation and prostate cancer cell growth
Zhiming Yang, Yu-Jia Chang, Hiroshi Miyamoto, et al.
Frontiers in Pharmacology
|
October 5, 2023
Utility of pharmacogenetic testing to optimise antidepressant pharmacotherapy in youth: a narrative literature review
Bradley Roberts, Zahra Cooper, Stephanie Lu, et al.
Investigational New Drugs
|
April 12, 2012
Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg/m(2) every 21 days in patients with cancer
Glen J Weiss, Ross C Donehower, Tara Iyengar, et al.
Echocardiography (Mount Kisco, N.Y.)
|
April 13, 2012
Implications of acute left ventricular remodeling during squatting stress echocardiography
P Anthony N Chandraratna, Dilbahar S Mohar, Peter F Sidarous, et al.
Page
of 39